{"id":50645,"date":"2022-11-09T09:02:04","date_gmt":"2022-11-09T08:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/valbiotis-successfully-completes-a-fundraise-of-9-7-million-euros\/"},"modified":"2022-11-09T09:02:04","modified_gmt":"2022-11-09T08:02:04","slug":"valbiotis-successfully-completes-a-fundraise-of-9-7-million-euros","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/valbiotis-successfully-completes-a-fundraise-of-9-7-million-euros\/","title":{"rendered":"Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros"},"content":{"rendered":"
\n

LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nValbiotis (FR0013254851 \u2013 ALVAL, PEA \/ SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today announces the success of its fundraise for approximatively \u20ac 9.7 millions, including, on the one hand, a reserved offer intended to a category of investors via an accelerated bookbuilding for approximately \u20ac9.0 million, and, on the other hand, an offer to the public intended to individual shareholders via the PrimaryBid platform of approximately \u20ac0.7 million (the \u201cGlobal Offer\u201d).\n<\/p>\n

\nS\u00e9bastien PELTIER, Chairman of the Valbiotis Board of Directors, states: \u201cI would like to thank all the investors, both historical and new, who participated in this fundraise to support the Company\u2019s strategic acceleration. I am particularly pleased with the support of the hundreds of individual shareholders who were able to participate via the PrimaryBid platform. This fundraising will offer our portfolio of four active substances in the advanced development phase a chance of success, thanks to future international partnerships, which will be added to the one already signed with Nestl\u00e9 Health Science for TOTUM\u202263, and direct marketing in France of our three other products, TOTUM\u2022070, TOTUM\u2022854 and TOTUM\u2022448. A new strategy that opens up prospects for the Company\u2019s rapid growth in turnover.\u201c<\/i>\n<\/p>\n

\nAllocation of funds\n<\/p>\n

\nAs previously announced, proceeds from the offering will be used to fund:\n<\/p>\n

\n– at 60%, the Company’s structuring to support future global or regional (except France) licensing and\/or distribution partnerships for the other TOTUM products in the pipeline (TOTUM\u2022070 \u2013 LDL hypercholesterolemia; TOTUM\u2022448 \u2013 NAFL\/NASH; TOTUM\u2022854 \u2013 raised blood pressure) and to support the licensing and supply agreements already signed for TOTUM\u202263 (prediabetes). It should be recalled that TOTUM\u202263 (prediabetes) is licensed at Nestl\u00e9 Health Science, and the results of the Phase II\/III REVERSE-IT pivot study are now expected in the first half of 2023 (as announced by the Company on 15 September 2022<\/a>). From a regulatory point of view, TOTUM\u202263 is already marketable in Europe, after notification to the DGCCRF in France (mutual recognition applicable for other European Union countries). The results of REVERSE-IT are ultimately intended to enable a health claim to be made. Valbiotis’ goal is to finalize the signature of an international licensing and\/or distribution agreement by the second half of 2023 for TOTUM\u2022070;\n<\/p>\n

\n– at 40%, the implementation of resources dedicated to the direct marketing of TOTUM products in France (excluding TOTUM\u202263) in accordance with the strategy communicated on October 7 (press release of October 7, 2022<\/a>). The marketing strategy will be based on in-house medical sales representatives (APMs) whose main target audience will be key prescribers, i.e., general practitioners, certain specialists and pharmacists. The latter will recommend the TOTUM products based on their patients’ cardiometabolic profile. At the same time, consumers\/patients will be targeted directly through an adapted digital marketing strategy. The distribution channels envisaged will be pharmacies, drugstores and online sales. The funds raised will contribute to:\n<\/p>\n